PRO-1562
/ Progentos Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 18, 2026
A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis
(clinicaltrials.gov)
- P1/2 | N=160 | Not yet recruiting | Sponsor: Progentos Therapeutics
New P1/2 trial • CNS Disorders • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis
1 to 1
Of
1
Go to page
1